Related Experiment Video
Updated: Jul 3, 2026
05:59
An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
Published on: November 4, 2022
Clinical relevance of dissolution testing in quality by design
Paul A Dickinson1, Wang Wang Lee, Paul W Stott
1Pharmaceutical & Analytical R&D, AstraZeneca, Macclesfield, Cheshire, SK10 2NA, England.
The AAPS Journal
|August 8, 2008
Summary
Quality by Design (QbD) enhances pharmaceutical development by linking manufacturing to clinical performance. Dissolution testing, within QbD, can predict bioavailability and ensure product quality, optimizing regulatory flexibility.
Area of Science:
- Pharmaceutical Science
- Drug Development
- Regulatory Science
Background:
- Quality by Design (QbD) is emerging in pharmaceutical development for flexible regulatory approaches.
- Linking product design and manufacturing to clinical quality is crucial for optimizing drug development.
- Current biopharmaceutical classification system (BCS) and bioequivalence guidelines offer a foundation for dissolution testing's regulatory use.
Purpose of the Study:
- To explore the integration of in vitro dissolution testing within Quality by Design (QbD) frameworks.
- To demonstrate how dissolution testing can link manufacturing attributes to clinical performance.
- To provide a case study for applying QbD principles to enhance dissolution testing's relevance.
Main Methods:
- Literature review on QbD implementation in pharmaceutical regulation.
- Analysis of biopharmaceutical classification system (BCS) and bioequivalence guidelines.
- Case study application for a BCS Class II compound, linking dissolution to pharmacokinetic variables.
Main Results:
- QbD enables a more risk-based and efficient regulatory pathway by focusing on product and process understanding.
- In vitro dissolution testing, when aligned with QbD, can serve as a reliable surrogate for in vivo performance.
- The study identified key aspects for linking dissolution testing to clinical relevance within QbD.
Conclusions:
- Further development of dissolution testing in the context of QbD is needed to fully leverage its potential.
- Optimizing in vitro dissolution test conditions and interpretation is essential for predicting in vivo outcomes.
- Successful QbD implementation requires a clear link between manufacturing variables, dissolution profiles, and clinical performance.
Related Concept Videos
01:10In Vitro Drug Release Testing: Overview, Development and Validation
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
01:13In Vitro Drug Dissolution: Compendial Testing Models I
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
01:17In Vitro Drug Dissolution: Alternative Methods
Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...
01:09In Vitro Drug Dissolution: Compendial Testing Models II
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients, maintaining...